Australia Veterinary Healthcare - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The australia veterinary healthcare market size is expected to grow from USD 1.29 billion in 2025 to USD 1.39 billion in 2026 and is forecast to reach USD 1.98 billion by 2031 at 7.36% CAGR over 2026-2031. This report is Segmented by Product (Therapeutics [Vaccines, Parasiticides, and More], Diagnostics [Immunodiagnostic Tests, Molecular Diagnostics, and More]), Animal Type (Dogs and Cats, Horses, and More), Route of Administration (Oral, Parenteral, and More), End User (Veterinary Hospitals & Clinics, Reference Laboratories, and More). The Market Forecasts are Provided in Terms of Value (USD).

Australia Veterinary Healthcare Market Trends and Insights

Rising Animal-Health Expenditure Among Pet Owners

Households spend between AUD 1,500 and AUD 3,000 (USD 975 to USD 1,950) per pet per year, with veterinary care accounting for up to 20% of those outlays. Insurance penetration climbed by double digits in 2024-2025 and now covers nearly one in five animals, enabling costly interventions such as orthopedic surgery and oncology to proceed without liquidity constraints. Telehealth reimbursement lowers barriers to early diagnosis, and corporate wellness subscriptions lock in repeat visits by spreading fees across the year. These mechanisms stabilize clinic revenue and fund investments in diagnostics that reinforce the growth trajectory of the Australian veterinary healthcare market.

Expansion of Livestock Export Volumes and Values

Australia shipped 766,044 head of cattle and 433,078 sheep in 2024, underpinned by livestock product value of AUD 38.6 billion (USD 25.1 billion). Disease-free status is critical for market access, prompting producers to intensify vaccination and parasite-control programs. Climate volatility heightens parasite load, steering demand toward long-acting injectables and multivalent vaccines that align with extensive grazing practices. China’s reopening to additional Australian plants and Indonesia’s appetite for feeder cattle are expected to boost therapeutics consumption, reinforcing the Australian veterinary healthcare market outlook.

Other drivers and restraints analyzed in the detailed report include:

• Uptake of Advanced Diagnostics
• Traceability-Linked Demand for eID-Enabled Health Tech
• High Cost of Veterinary Services and Pharmaceuticals
• Rural Workforce Shortages Limiting Service Access

Segment Analysis

Diagnostics started from a smaller base yet are growing at a 9.85% CAGR, outpacing therapeutics, which held 62.55% of the Australian veterinary healthcare market share in 2025. Point-of-care chemistry and hematology systems shorten turnaround to minutes and keep revenue in-house, lifting clinic profitability. Vaccines dominate therapeutics, with combination shots reducing visits and enhancing compliance. Parasiticides gain from tick range expansion, while antimicrobial stewardship tempers anti-infective use.

Diagnostic imaging remains capital-intensive, yet corporate chains deploy radiography and ultrasound to differentiate their services. Molecular PCR panels gained poultry traction amid avian-influenza vigilance, compressing detection from 48 hours to 4 hours and reinforcing demand across the Australia veterinary healthcare market.

Dogs and cats accounted for 45.53% of 2025 revenue, reflecting high pet ownership, but poultry is forecast to grow at an 8.75% CAGR as biosecurity investments scale. Mandatory surveillance and hatchery vaccination protect a sector that produces 1.3 million tonnes of meat annually, anchoring the uptake of therapeutics and diagnostics. Equine and swine remain niche yet high-value, while sheep and goats benefit from electronic identification that tightens residue compliance, broadening opportunities across the Australia veterinary healthcare market size for these subsegments

Complete Report Scope:

• By Product
  • Therapeutics
    • Vaccines
    • Parasiticides
    • Anti-Infectives
    • Medical Feed Additives
    • Other Therapeutics
  • Diagnostics
    • Immunodiagnostic Tests
    • Molecular Diagnostics
    • Diagnostic Imaging
    • Clinical Chemistry
    • Point-of-Care Testing Devices
• By Animal Type
  • Dogs and Cats
  • Horses
  • Swine
  • Poultry
  • Other Animal Types
• By Route of Administration
  • Oral
  • Parenteral
  • Topical
  • Others
• By End User
  • Veterinary Hospitals & Clinics
  • Reference Laboratories
  • Point-of-Care / In-House Testing Settings
  • Academic & Research Institutes

List of Companies Covered in this Report:

• Abbey Animal Health
• Apiam Animal Health Ltd
• Boehringer Ingelheim
• Ceva Santé Animale
• Chemvet Australia
• Covetrus
• Dechra Pharmaceuticals
• Delvet Pty Ltd
• Elanco
• Greencross Ltd
• Henry Schein Animal Health
• IDEXX
• iM3 Pty Ltd
• Jurox
• MSD Animal Health (Merck & Co.)
• National Veterinary Care
• Neogen Australasia
• QBiotics Group Ltd
• Vetoquinol
• Virbac
• Zoetis

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support